Afluria is a flu vaccine that comes in several varieties for children and adults, including one with a needle-free delivery system called PharmaJet. Afluria was associated with a 23% risk of fever in children under 3 years old in clinical trials.
What happened with the 2010 vaccine?
Can Afluria cause the flu?
How is Afluria given?
When should I get a flu shot?
How many shots do I need?
Who should NOT get Afluria?
What is Guillain-Barre Syndrome?
How long does it take for Afluria to work?
How long does Afluria protect me from the flu?
What are common Afluria vaccine side effects?
What are severe side effects of Afluria?
What is in Afluria?
Where can I get more information?
Afluria is an immunization against influenza (“the flu”). There are several versions approved in the United States:
- Afluria Trivalent: Flu shot approved in 2007 for active immunization of people who are at least 6 months old against 3 types of influenza virus subtypes A and B. It is manufactured by CSL Limited and distributed by Merck & Co.
- Afluria Trivalent (Thimerosal-Free): Flu shot for children over 6 months old with no preservative. It is manufactured by Seqirus.
- Afluira Quadrivalent (PharmaJet Needle-Free): Approved in 2016 for immunization of adults 18 and older against 4 types of influenza virus subtypes A and B. It is manufactured by Seqirus.
CSL’s 2010 Southern Hemisphere flu shot was linked to increased reports of fever and febrile seizures (fever-induced seizures) in children under the age of 5 years old compared to previous years.
The Advisory Committee on Immunization Practices (ACIP) recommends that Afluria should not be used in children aged 6 months through 8 years because of increased risk for febrile reactions noted in this age group with Seqirus’ 2010 Southern Hemisphere IIV3.
Afluria Quadrivalent is given in a single 0.5-mL shot in the upper arm. It can be administered with a needle or with PharmaJet Needle-Free Injection System that uses a thin jet of water to deliver the vaccine.
Afluria Trivalent is given in a single 0.25-mL shot in the thigh in infants, and in the upper arm in toddlers and young children.
No. Afluria contains an inactivated (dead) virus that can’t cause the flu, but stimulates the antibodies to develop immunity. This can cause mild flu-like symptoms in some people, but not the flu.
Each year’s new flu shot is usually available by August. You should get a flu shot between Halloween and Thanksgiving. Flu season in the United States peaks between December and March in most years.
Children 6 months through 35 months of age should receive one 0.25-mL dose of Afluria Trivalent, unless they have never been vaccinated, in which case they should get two 0.25-mL doses: One on day 1 followed by another approximately 2 weeks later.
Children 36 months through 8 years old should receive one 0.5-mL dose of Afluria Trivalent, unless they have never been vaccinated, in which case they should get two 0.5-mL doses: One on day 1 followed by another approximately 4 weeks later.
Children over 9 years old should get a single 0.5-mL dose of Afluria Trivalent.
Adults can get a single 0.5-mL dose of Afluria Trivalent or Afluria Quadrivalent.
Afluria is contraindicated in people with known severe allergic reactions (e.g. anaphylaxis) to any component of the vaccine, including egg protein, or to a previous flu shot.
Guillain-Barré Syndrome (GBS) is a severe reaction that can occur within 6 weeks of Afluria and cause nerve damage, paralysis, disability, and death. It is estimated to occur in slightly more than one in a million flu shots. The 1976 swine flu outbreak resulted in mass-vaccination and an increased rate of GBS.
The full effect of Afluria is generally achieved around 3 weeks after vaccination.
It depends on what type of flu viruses are circulating around the world. Even in the best case scenario, flu shots are only around 50% effective at protecting you from the flu. The effectiveness goes down over time, which is why you need a new flu shot every year.
In children, the most common side effects of Afluria Trivalent were pain, redness, and swelling where the shot was given, irritability, runny nose, fever, cough, loss of appetite, vomiting/diarrhea, headache, muscle aches, ear ache, wheezing, and sore throat.
Fevers occurred in 23% of children between the ages of 6 months and 3 years old after the 1st dose, and 23% after the 2nd dose of Afluria.
Fevers occurred in 16% of children between the ages of 3 years and 9 years old after the 1st dose, and 8% after the 2nd dose.
In adults 18-64 years old, the most commonly reported injection-site reactions of Afluria Quadrivalent were pain (40%), muscle pain (20%), and headache (20%).
The most common side effects of Afluria Trivalent using the PharmaJet needle-free injection system were tenderness (80%), redness (60%), itching (20%), bruising (10%), muscle pain (30%), tiredness (30%), and headache (20%).
Afluria is associated with the following mild side effects:
- Ear ache
- Hematoma (blood pocket)
- Muscle ache
- Runny nose
- Shortness of breath
- Sore throat
- Upper respiratory tract infection
- Allergic reaction
- Brachial plexus neuropathy
- Febrile seizures
- Flu-like illness
- Guillain-Barré Syndrome
- Hypersensitivity reactions
- Kidney problems
- Large injection-site swelling
- Neuritis or neuropathy (nerve damage)
- Optic neuritis
- Partial facial paralysis
- SIRVA (Shoulder Injury Related to Vaccine Administration)
- Serum sickness
- Transverse myelitis
- Vasculitis with transient renal involvement
Ingredients in Afluria Trivalent (0.5-mL dose): Beta-propiolactone, thimerosol (multi-dose vials only), monobasic sodium phosphate, dibasic sodium phosphate, monobasic potassium phosphate, potassium chloride, calcium chloride, sodium taurodeoxycholate, neomycin sulfate, polymyxin B, egg protein, sucrose.
Thimerosal, a mercury-based preservative, is not used in the single-dose versions of Afluria, but the multi-dose vaccines do contain thimerosal. Each 0.5-mL dose contains 24.5 mcg of mercury.
Ingredients in Afluria Quadrivalent (0.5-mL dose) Sodium chloride (4.1-mg), monobasic sodium phospate (80-mcg), dibasic sodium phosphate (300 mcg), monobasic potassium phosphate (20 mcg), potassium chloride (20 mcg), calcium chloride (0.5-mcg). From the manufacturing process, each dose may also contain residual sodium taurodeoxycholate (≤ 10 ppm), ovalbumin (< 1 mcg), sucrose (< 10 mcg), neomycin sulfate (≤ 81.8 nanograms [ng]), polymyxin B (≤ 14 ng), and beta-propiolactone (≤ 1.5 ng).